全文获取类型
收费全文 | 37880篇 |
免费 | 2264篇 |
国内免费 | 199篇 |
专业分类
耳鼻咽喉 | 372篇 |
儿科学 | 808篇 |
妇产科学 | 762篇 |
基础医学 | 5113篇 |
口腔科学 | 1997篇 |
临床医学 | 2833篇 |
内科学 | 9717篇 |
皮肤病学 | 984篇 |
神经病学 | 3378篇 |
特种医学 | 798篇 |
外国民族医学 | 4篇 |
外科学 | 5496篇 |
综合类 | 174篇 |
一般理论 | 10篇 |
预防医学 | 3054篇 |
眼科学 | 755篇 |
药学 | 2126篇 |
中国医学 | 198篇 |
肿瘤学 | 1764篇 |
出版年
2023年 | 286篇 |
2022年 | 381篇 |
2021年 | 1434篇 |
2020年 | 801篇 |
2019年 | 1219篇 |
2018年 | 1500篇 |
2017年 | 889篇 |
2016年 | 916篇 |
2015年 | 1146篇 |
2014年 | 1577篇 |
2013年 | 1952篇 |
2012年 | 2897篇 |
2011年 | 3198篇 |
2010年 | 1690篇 |
2009年 | 1518篇 |
2008年 | 2405篇 |
2007年 | 2464篇 |
2006年 | 2327篇 |
2005年 | 2105篇 |
2004年 | 1875篇 |
2003年 | 1675篇 |
2002年 | 1555篇 |
2001年 | 458篇 |
2000年 | 464篇 |
1999年 | 425篇 |
1998年 | 283篇 |
1997年 | 238篇 |
1996年 | 200篇 |
1995年 | 162篇 |
1994年 | 135篇 |
1993年 | 149篇 |
1992年 | 216篇 |
1991年 | 205篇 |
1990年 | 193篇 |
1989年 | 123篇 |
1988年 | 109篇 |
1987年 | 88篇 |
1986年 | 116篇 |
1985年 | 110篇 |
1984年 | 85篇 |
1983年 | 67篇 |
1982年 | 65篇 |
1981年 | 60篇 |
1979年 | 49篇 |
1978年 | 42篇 |
1976年 | 35篇 |
1974年 | 35篇 |
1972年 | 36篇 |
1971年 | 37篇 |
1970年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
991.
Eugenia Sánchez Rodríguez Raquel Ríos León Francisco Mesonero Gismero Agustín Albillos Antonio Lopez-Sanroman 《Gastroenterologia y hepatologia》2018,41(10):629-635
Introduction
Thiopurine therapy can be optimised by determining the concentration of the drug's metabolites.Patients and methods
Retrospective analysis on a prospective database of 31 patients with inflammatory bowel disease who failed therapy with thiopurines. Thiopurine metabolites (6-thioguanine, 6-TGN and 6-methylmercaptopurine, 6-MMP) were measured by high-performance liquid chromatography (Laboratorios Cerba, Barcelona) and treatment was duly adjusted in accordance with the results. Clinical response was reassessed after six months.Result
Despite the appropriate theoretical dose of thiopurines being administered, the dose was insufficient in 45.6% of patients (nonadherence to treatment suspected in 6.45%) and 16.2% received an excessive dose or the drug was metabolised by other metabolic pathways. After treatment was optimised based on metabolite levels, only 25.8% (8/31) were prescribed a biological agent, while 74.2% of cases (23/31) were managed through dose optimisation alone.Discussion
Monitoring thiopurine metabolite levels may help clinicians to assess non-responsive patients before adding or switching to another drug (generally a biological agent), thereby avoiding any additional costs or potential toxicity. This strategy may also help to identify patients receiving an insufficient dose and those with an alternative metabolic pathway, who could be candidates for low-dose AZA with allopurinol, as well as patients who are suspected of being non-adherent. In three out of four patients, switching to a biological agent can be avoided. 相似文献992.
Rodrigo A. Giacaman Sebastián Torres Yenifer Gómez Cecilia Muñoz-Sandoval Jens Kreth 《Archives of oral biology》2015
Objective
This study was conducted to estimate oral colonization by Streptococcus mutans and Streptococcus sanguinis in adults with high and without any caries experience. Furthermore, differences in the amount of hydrogen peroxide (H2O2) produced by S. sanguinis isolated from both groups were assessed.Design
Forty adults were divided into: (i) carious lesion-free, without any carious lesion, assessed by the International Caries Detection and Assessment System (ICDAS), or restoration, (CF) and (ii) high caries experience (HC). Saliva samples were collected and seeded on respective agar-plates for enumeration of total streptococci, S. mutans and S. sanguinis (CFU/mL) and compared between groups. Additionally, S. sanguinis colonies obtained from both groups were inoculated on Prussian blue agar for H2O2 detection. Production of H2O2 was quantified and compared between the two groups. S. sanguinis counts were significantly higher in CF than HC individuals (p < 0.05). Conversely, S. mutans showed significantly higher levels in HC than CF subjects (p < 0.001). S. sanguinis colonies from CF individuals produced significantly larger H2O2 halos compared with HC subjects.Conclusions
S. sanguinis predominates over S. mutans in saliva of adults without caries experience. In those people, S. sanguinis produces more H2O2ex vivo. 相似文献993.
994.
Silvia T Elias Gabriel A Borges Danilo A Amorim Daniela F Rêgo Luiz A Simeoni Dâmaris Silveira Yris Maria Fonseca-Bazzo José E Paula Christopher William Fagg Ivelone M C Barros Wenzel C Abreu Décio S Pinto-Júnior Pérola O Magalhães Francisco A R Neves Adriana Lofrano-Porto Eliete N S Guerra 《Clinical oral investigations》2015,19(3):637-646
995.
Influence of Intraoral Temperature and Relative Humidity on the Dentin Bond Strength: An in Situ Study 下载免费PDF全文
Letícia O. Saraiva DDS MS Thaiane R. Aguiar DDS MS PhD Leonardo Costa DDS MS Andrea N. Cavalcanti DDS MS PhD Marcelo Giannini DDS MS PhD Paula Mathias DDS MS PhD 《Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.]》2015,27(2):92-99
996.
997.
Zachary P. Soucy DO Lisa Mills MD John S. Rose MD Kenneth Kelley MD Francisco Ramirez Nathan Kuppermann MD MPH 《Journal of ultrasound in medicine》2015,34(8):1473-1478
Over the past decade, point‐of‐care ultrasound has become a common tool used for both procedures and diagnosis. Developing high‐fidelity phantoms is critical for training in new and novel point‐of‐care ultrasound applications. Detecting skull fractures on ultrasound imaging in the younger‐than‐2‐year‐old patient is an emerging area of point‐of‐care ultrasound research. Identifying a skull fracture on ultrasound imaging in this age group requires knowledge of the appearance and location of sutures to distinguish them from fractures. There are currently no commercially available pediatric skull fracture models. We outline a novel approach to building a cost‐effective, simple, high‐fidelity pediatric skull fracture phantom to meet a unique training requirement. 相似文献
998.
999.
Giuseppe Citerio Jan Bakker Matteo Bassetti Dominique Benoit Maurizio Cecconi J. Randall Curtis Gordon S. Doig Margaret Herridge Samir Jaber Michael Joannidis Laurent Papazian Anders Perner Mark J. Peters Pierre Singer Martin Smith Marcio Soares Antoni Torres Antoine Vieillard-Baron Jean-François Timsit Elie Azoulay 《Intensive care medicine》2015,41(2):179-191
1000.
Stem cell bioengineering strategies to widen the therapeutic applications of haematopoietic stem/progenitor cells from umbilical cord blood 下载免费PDF全文
Pedro Z. Andrade Francisco dos Santos Joaquim M. S. Cabral Cláudia L. da Silva 《Journal of tissue engineering and regenerative medicine》2015,9(9):988-1003
Umbilical cord blood (UCB) transplantation has observed a significant increase in recent years, due to the unique features of UCB haematopoietic stem/progenitor cells (HSCs) for the treatment of blood‐related disorders. However, the low cell numbers available per UCB unit significantly impairs the widespread use of this source for transplantation of adult patients, resulting in graft failure, delayed engraftment and delayed immune reconstitution. In order to overcome this issue, distinct approaches are now being considered in clinical trials, such as double‐UCB transplantation, intrabone injection or ex vivo expansion. In this article the authors review the current state of the art, future trends and challenges on the ex vivo expansion of UCB HSCs, focusing on culture parameters affecting the yield and quality of the expanded HSC grafts: novel HSC selection schemes prior to cell culture, cytokine/growth factor cocktails, the impact of biochemical factors (e.g. O2) or the addition of supportive cells, e.g. mesenchymal stem/stromal cell (MSC)‐based feeder layers) were addressed. Importantly, a critical challenge in cellular therapy is still the scalability, reproducibility and control of the expansion process, in order to meet the clinical requirements for therapeutic applications. Efficient design of bioreactor systems and operation modes are now the focus of many bioengineers, integrating the increasing 'know‐how' on HSC biology and physiology, while complying with the GMP standards for the production of cellular products, i.e. through the use of commercially available, highly controlled, disposable technologies. Copyright © 2013 John Wiley & Sons, Ltd. 相似文献